IDIBELL on the media
Bellvitge Hospital incorporates voice-based artificial intelligence in the follow-up of patients with severe asthma
This is the first time that this technology has been applied to asthma in Spain. Some months ago, this IDIBELL and HUB group launched a mobile app for the follow-up of this disease.
Mutua Madrileña Foundation supports a Bellvitge project that will promote the clinical use of bioartificial kidneys
The study, led by Dr. Miguel Hueso, will help create alternatives to organ donation and dialysis for the treatment of chronic diseases, and the development of new drugs.
Bellvitge contributes to a significant improvement in the treatment of hereditary angioedema
Researchers from Bellvitge University Hospital (HUB) and IDIBELL have participated in a clinical trial that has demonstrated the efficacy of sebetralstat, a new oral treatment for hereditary angioedema attacks.
A genetic test will improve the diagnosis of a rare cancer predisposition syndrome in children
Researchers have developed a genetic test that will improve the diagnosis of CMMRD, a rare cancer predisposition syndrome in children. The analysis of only a selection of genetic segments allows this test to be fast and accessible to healthcare professionals.
Researchers discover biomarkers that predict response to immunotherapy in skin carcinoma
IDIBELL researchers have discovered a mechanism by which tumor cells respond differentially to various immunotherapies and have identified biomarkers that predict the response to these drugs. Published in Nature Communications, this finding would allow personalizing the treatment of skin carcinoma and thus increase the patients quality of life.
New Queer Group at IDIBELL to promote diversity in biomedical research
At IDIBELL, we are proud to announce that this month the negotiating table for the first IDIBELL LGBTIAQ+ Plan has been constituted. Additionally, IDIBELL is inviting members to join the new Queer group, a meeting space for the LGBTIAQ+ community.
Fecal microbiota transplantation emerges as a safe and effective alternative to antibiotics for C. difficile infection
150 recurrent cases of C. difficile in Catalonia could be treated with Fecal Microbiota Transplantation each year
Telemedicine improves follow-up of patients with advanced hematological treatments
Recent research by the Hematology and Digital Health groups of IDIBELL and ICO shows that the use of smart watches and mobile apps improves the follow-up of patients who have received a bone marrow transplant or CAR-T therapy.
The role of the epidermal growth factor receptor in chronic liver damage has been proven
Researchers from IDIBELL, CIBER and the Complutense University, led by Dr. Isabel Fabregat, link EGFR signaling to fibrotic and inflammatory processes in the liver. The findings, obtained with a mouse model, could be transferred to patients suffering from a fibrotic process.
More than a hundred experts meet in Barcelona to discuss the latest advances in the treatment of onco-haematological diseases
M. Carolina Florian and Alessandra Giorgetti, group leaders of the Regenerative Medicine Program at IDIBELL, are part of the organizing committee. The congress featured more than ten national and international speakers, and 135 participants.